The target audience is pharmacists who care for patients with ovarian cancer as well as other stakeholders in hematology/oncology practice.
The goal of this activity is to improve the knowledge, confidence, and competence of learners in the management of patients with ovarian cancer.
Upon completion of this activity, participants should be able to:
Analyze current and emerging practice-changing data on PARP inhibitors as single agents or in combination therapies for ovarian cancer
Design individualized treatment strategies for patients with newly diagnosed and recurrent or relapsed ovarian cancer that incorporate novel therapies and combination strategies
Determine maintenance therapy for patients with ovarian cancer with or without BRCA mutations or other homologous recombination repair deficiencies in the frontline and relapsed settings
Provide patient education regarding treatment regimens and manage treatment-related adverse events to improve adherence and deliver patient-centered care
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Sarah Hayward, PharmD, BCOP
Clinical Pharmacy Specialist, Gynecologic OncologyStephenson Cancer Center at OU Health Oklahoma City, Oklahoma
Sarah Hayward, PharmD, BCOP: consultant/advisor/speaker: Immunogen, Merck, Seagen/Genmab.
Amy Indorf, PharmD, BCOP
Clinical Assistant Professor
University of Washington
School of Pharmacy
Clinical Oncology Pharmacist
Fred Hutchinson Cancer Center
Amy Ly Indorf, PharmD, BCOP, has no relevant financial relationships to disclose.
The planners and content peer reviewers from ProCE, LLC and Clinical Care Options, LLC have no relevant financial relationships to disclose.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is jointly provided by ProCE, LLC, Clinical Care Options, LLC, and the Society of Infectious Diseases Pharmacists (SIDP). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-23-012-H01-P has been assigned to this home study application-based activity. This activity is approved for 1 contact hours (0.10 CEUs) in states that recognize ACPE providers. This activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 65 or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.